v3.21.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Cash flows from operating activities:      
Net loss $ (3,023,935) $ (1,906,527)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 100,687 110,882  
Amortization of loan discount and fees 223,065 52,140  
Stock-based compensation 36,976 49,932  
Change in fair value of warrant liability (562)    
Change in credit reserve 3,335 (58,132)  
Changes in operating assets and liabilities:      
Accounts receivable, net 22,700 45,637  
Due from factor, net (6,950) (67,378)  
Inventory 573,496 30,224  
Other current assets (195,027) 155,411  
Accounts payable 195,528 1,135,762  
Accrued expenses and other liabilities 98,075 (608,047)  
Deferred revenue (1,667) (15,231)  
Accrued compensation - related party (62,777) (16,107)  
Accrued interest 394,479 251,230  
Net cash (used in) provided by operating activities (1,642,577) (840,204)  
Cash flows from investing activities:      
Cash acquired in business combination   106,913  
Deposits   43,510  
Net cash provided by investing activities   150,423  
Cash flows from financing activities:      
Proceeds from related party advances   122,414  
Advances from factor 32,617 180,552  
Proceeds from venture debt   250,000  
Issuance of loans payable 1,347,050    
Issuance of convertible notes payable 528,650    
Proceeds from Issuance of Convertible Preferred Stock   428,926  
Subscription receivable from Series A-3 preferred stock   (117,614)  
Offering costs (130,523) (43,353)  
Net cash provided by (used in) financing activities 1,777,794 820,925  
Net increase (decrease) in cash and cash equivalents 135,217 131,144  
Cash and cash equivalents at beginning of period 575,986 40,469 $ 40,469
Cash and cash equivalents at end of period $ 711,203 171,613 $ 575,986
Supplemental disclosure of non-cash investing and financing activities:      
Venture debt issued in exchange of forgiveness of accrued interest   209,211  
Warrants issued for offering costs   918  
Warrants issued with venture debt   58,421  
Issuance of promisosry note payable in acquisition   4,500,000  
Issuance of Series B preferred stock in acquisition   $ 11,000,000